Evidence map›Paper›PMID 38247000›Full record

ReviewTranslational neurodegeneration2024

The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases.

Arazu Sharif, John Mamo, Virginie Lam, Hani Al-Salami, Armin Mooranian, Gerald F Watts, Roger Clarnette, Giuseppe Luna, Ryu Takechi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Neuroinflammation plays a crucial role in the pathogenesis of Parkinson's disease: a systematic review and meta-analysis of clinical and biomarker evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Arazu SharifCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
John MamoCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Virginie LamCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Hani Al-SalamiCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Armin MooranianCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Gerald F WattsSchool of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia.
Roger ClarnetteSchool of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia.
Giuseppe LunaCurtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Ryu TakechiCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia. r.takechi@curtin.edu.au.ORCID 0000-0001-6359-3382
Curtin University · AUThe University of Western Australia · AU

Funding

Medical Research Future Fund MRF1201204National Health and Medical Research Council GNT2001090
6 · The paper itself

Abstract

Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood-brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and cognitive impairment associated with diabetes.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesParkinson DiseaseBlood-Brain BarrierHumansProbucolProbucolAmyloid-betaBlood–brain barrierInflammationNeurodegenerative diseaseOxidative stressProbucolProbucol analogues

Identifiers

PMID38247000
PMCPMC10802046
OpenAlexW4391101040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.